Aurora Cannabis Inc stock is up another 21% after a 46% rally in prior session. The Canada-based global medical cannabis company reported a third-quarter fiscal 2025 net revenue of CA$88.2 million, compared to CA$64.4 million a year ago.

Senate actions also provided fuel for cannabis stocks to rise on Wednesday, with one committee looking into easing regulations for banks to handle transactions related to legal cannabis businesses, while the full Senate is expected to confirm President Donald Trump’s nominee to lead the Department of Health and Human Services, Robert F. Kennedy Jr., who is seen as a proponent of legal pot.

The 37% increase from the prior period was mainly due to 51% growth in the global medical cannabis business and 22% in the plant propagation business, slightly offset by lower quarterly revenue in the consumer cannabis business.

Consolidated adjusted gross margin was 65% in the third quarter and 53% in the prior-year quarter. Adjusted gross profit was CA$56.0 million in the third quarter vs. CA$33.6 million in the prior year quarter, an increase of 67%.

Medical cannabis net revenue was CA$68.1 million, a 51% increase from the prior-year quarter, driven by CA$23.1 million was primarily due to higher sales to Australia, Germany, Poland and the UK, as well as increased revenue in Canada to insurance covered and self-paying patients.

The adjusted gross margin reached 74%, compared to 63% in the prior year quarter, through sustainable cost reductions, higher selling prices, and improved efficiency in production operations, including sourcing for Europe from Canada.

Aurora’s consumer cannabis net revenue was CA$9.9 million, a 15% decrease compared to $11.6 million in the prior year quarter, mainly due to the decision to prioritize the supply of GMP manufactured products to high-margin global medical cannabis business rather than the consumer business, which offers lower margins.